We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

44 hedge funds and large institutions have $7.26M invested in Oncolytics Biotech in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

33% more funds holding

Funds holding: 33 → 44 (+11)

1.26% less ownership

Funds ownership: 8.59% → 7.33% (-1.3%)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

46% less capital invested

Capital invested by funds: $13.6M → $7.26M (-$6.3M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
44
Holders Change
+11
Holders Change %
+33.33%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
16
Increased
6
Reduced
10
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$626K
2
Citadel Advisors
Citadel Advisors
Florida
+$178K
3
ARC
Advisor Resource Council
Texas
+$156K
4
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$86.9K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$47.4K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$2.33M
2
Millennium Management
Millennium Management
New York
-$133K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$73K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$48.8K
5
Squarepoint
Squarepoint
New York
-$25.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$8.24K +$2.15K +1,374 +29%
CMA
27
Cedar Mountain Advisors
Oregon
$7.63K – – –
UBS Group
28
UBS Group
Switzerland
$6.34K -$4.64K -2,966 -39%
Wells Fargo
29
Wells Fargo
California
$6.3K -$2.4K -1,537 -25%
National Bank of Canada
30
National Bank of Canada
Quebec, Canada
$4.91K +$33 +21 +0.6%
Toronto Dominion Bank
31
Toronto Dominion Bank
Ontario, Canada
$4.8K +$5.56K +3,554 New
FDCDDQ
32
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.36K -$1.15K -736 -18%
Carson Wealth (CWM LLC)
33
Carson Wealth (CWM LLC)
Nebraska
$3K – – –
Barclays
34
Barclays
United Kingdom
$1.62K +$625 +400 +50%
TWC
35
TD Waterhouse Canada
Ontario, Canada
$970 – – –
PCMC
36
Planning Capital Management Corporation
Pennsylvania
$291 +$336 +215 New
JFA
37
JNBA Financial Advisors
Minnesota
$284 – – –
HGA
38
Hobbs Group Advisors
South Carolina
$142 +$164 +105 New
CCMW
39
Cypress Capital Management (Wyoming)
Wyoming
$135 – – –
ASN
40
Advisory Services Network
Georgia
$135 +$156 +100 New
WWM
41
Wolff Wiese Magana
California
$42 – – –
HPC
42
HM Payson & Co
Maine
$38 +$44 +28 New
TRCT
43
Tower Research Capital (TRC)
New York
$23 +$27 +17 New
1832 Asset Management
44
1832 Asset Management
Ontario, Canada
$7 – – –
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
– -$73K -33,485 Closed
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
– -$48.8K -22,400 Closed
Squarepoint
47
Squarepoint
New York
– -$25.6K -11,725 Closed
IA
48
IFP Advisors
Florida
– -$4.36K -2,000 Closed
PNC Financial Services Group
49
PNC Financial Services Group
Pennsylvania
– -$2.61K -1,196 Closed
1
2

ONCY Hedge Fund Activity: Q4 2023 in Review

44 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2023, worth a combined $7.26M — down 46% from $13.6M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ONCY positions and 5 closed out — a net gain of 11 holders — while 6 added to existing stakes and 10 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $626K. The largest seller was Anson Funds Management, cutting an estimated $2.33M.

  • 44 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2023, up from 33 in Q3 2023.
  • Funds reported $7.26M of Oncolytics Biotech stock for Q4 2023, down 46% quarter-over-quarter.
  • 16 funds opened new Oncolytics Biotech positions in Q4 2023 and 5 closed out, a net change of +11 holders.
  • The largest Oncolytics Biotech buyer in Q4 2023 was Morgan Stanley, an estimated $626K added.
  • The largest Oncolytics Biotech seller in Q4 2023 was Anson Funds Management, an estimated $2.33M sold.

Based on aggregated 13F filings for Q4 2023.